Several injectable biologics now offer remarkably fast relief for moderate-to-severe atopic dermatitis, with some reducing itch in as little as 48 hours. Dupixent, the first biologic approved for this condition back in 2017, showed significant itch improvement as early as two days after the first injection, and the newer Nemluvio, approved in December 2024, demonstrated clinically meaningful itch reduction at 48 hours in a subset of patients. For the millions of people living with uncontrolled eczema who have cycled through topical steroids and other conventional treatments without adequate relief, these fast-acting injections represent a genuine shift in what is possible. What makes these treatments particularly relevant for readers of a brain health site is the well-documented connection between chronic skin inflammation, sleep disruption, and cognitive function.
Severe atopic dermatitis can rob people of hours of sleep every night due to relentless itching, and chronic sleep deprivation is one of the most consistent risk factors for cognitive decline and dementia. Treating the itch fast is not merely a dermatological concern — it is a neurological one. This article covers the FDA-approved injectable biologics currently available for moderate-to-severe atopic dermatitis, how quickly each one works, their comparative efficacy, and an investigational treatment on the horizon that may require dosing only once per year. We will also address the practical considerations older adults and caregivers should weigh when evaluating these options.
Table of Contents
- How Fast Do Injections for Moderate-to-Severe Atopic Dermatitis Actually Work?
- Comparing Approved Biologics — Efficacy, Mechanism, and Limitations
- The Itch-Sleep-Brain Connection — Why Dermatitis Treatment Matters for Cognitive Health
- Dosing Schedules and Practical Tradeoffs for Patients and Caregivers
- Who Should Not Use These Treatments — Warnings and Limitations
- EBGLYSS in Younger Patients — What the Latest Pediatric Data Shows
- The Future — Could One Injection Per Year Be Enough?
- Conclusion
- Frequently Asked Questions
How Fast Do Injections for Moderate-to-Severe Atopic Dermatitis Actually Work?
The speed of relief varies among the approved biologics, but all of them outperform the weeks-to-months timeline that many patients have come to expect from conventional treatments. Dupixent (dupilumab), which blocks both IL-4 and IL-13 inflammatory pathways, demonstrated significant itch improvement as early as two days after the first injection in clinical trials, with meaningful itch relief by two weeks and clear or almost-clear skin typically achieved by 16 weeks. Nemluvio (nemolizumab), approved in December 2024 for adults and patients 12 and older, targets a different pathway entirely — IL-31, which directly drives itch signaling in the nervous system. In clinical trials, 10.7% of patients on Nemluvio achieved clinically meaningful itch reduction at just 48 hours, compared with 2.9% on placebo. EBGLYSS (lebrikizumab), a selective IL-13 inhibitor approved in 2024, showed meaningful itch relief as early as two weeks and significant skin clearance as early as four weeks.
To put these timelines in perspective, older systemic treatments like cyclosporine could suppress eczema but came with kidney toxicity risks that made long-term use dangerous, while topical steroids often failed to control moderate-to-severe disease at all. The difference between waiting two days for itch relief versus two months — or never getting adequate relief — is not trivial, particularly for older adults whose skin barrier function is already compromised by aging. It is worth noting that “fast” in clinical trial language means statistically significant improvement across a study population. Individual responses vary considerably. Some patients notice dramatic improvement within the first week; others may need the full 16-week assessment period before the treatment’s benefits become clear.
Comparing Approved Biologics — Efficacy, Mechanism, and Limitations
The four FDA-approved injectable biologics for moderate-to-severe atopic dermatitis each target different parts of the inflammatory cascade, and their efficacy profiles reflect those mechanistic differences. Dupixent remains the most extensively studied, with 36–38% of patients achieving clear or almost-clear skin (IGA 0 or 1) versus 9–10% on placebo, and 44–51% achieving at least 75% improvement on the EASI scale versus 12–15% on placebo. Dupixent has also demonstrated sustained efficacy up to four years, which matters for a chronic, relapsing condition. Nemluvio’s unique value lies in its mechanism. As the first approved monoclonal antibody targeting the IL-31 receptor alpha, it addresses itch at its neurological source rather than just dampening the broader inflammatory response.
Its IGA success rates of 36–38% in the ARCADIA 1 and 2 trials were comparable to Dupixent, though its EASI-75 rates of 42–44% versus 29–30% on placebo reflect a somewhat different patient response profile. EBGLYSS achieved strong numbers in its recent pediatric Phase 3 trial reported in March 2026, with 63% of patients reaching EASI-75 versus 22% on placebo and 44% achieving clear or almost-clear skin versus 15% on placebo. Adbry (tralokinumab), another IL-13 inhibitor approved for patients 12 and older, provides an additional option, though it has generally been positioned behind Dupixent and the newer entries in clinical practice. However, none of these biologics works for everyone, and the placebo-adjusted response rates reveal that a meaningful percentage of patients will not achieve clear or almost-clear skin even after a full treatment course. If a patient does not respond adequately to one biologic after an appropriate trial period, switching to a treatment with a different mechanism — say, moving from an IL-13 inhibitor to Nemluvio’s IL-31 pathway — may be a reasonable next step. this is a conversation that requires a dermatologist’s input, not a decision to make based on advertising.
The Itch-Sleep-Brain Connection — Why Dermatitis Treatment Matters for Cognitive Health
The relationship between chronic itch, disrupted sleep, and brain health is more direct than most people realize. Atopic dermatitis is one of the most common causes of chronic sleep disruption, with studies consistently showing that patients with moderate-to-severe disease lose significant sleep to nighttime scratching. This is not merely uncomfortable — chronic sleep deprivation impairs memory consolidation, accelerates amyloid-beta accumulation in the brain, and is independently associated with increased dementia risk. For older adults already managing mild cognitive impairment or early-stage dementia, the added burden of severe itch and fragmented sleep can worsen confusion, agitation, and functional decline.
Caregivers of people with dementia who also have uncontrolled eczema often describe a vicious cycle: the person scratches at night, cannot articulate what is wrong, becomes agitated, and neither the patient nor the caregiver sleeps. In this context, a treatment that reduces itch within 48 hours is not a luxury — it is a meaningful intervention for quality of life and potentially for cognitive preservation. Nemluvio’s clinical trial data specifically measured sleep improvement, with patients reporting better sleep quality within the first weeks of treatment. This aligns with its mechanism of action: by blocking IL-31, the cytokine most directly responsible for itch signaling to the brain, Nemluvio may address the neurological component of itch more directly than biologics that work further upstream in the inflammatory cascade.
Dosing Schedules and Practical Tradeoffs for Patients and Caregivers
One of the most practical differences among these biologics is how often they need to be injected, which matters enormously for adherence — especially in older adults or patients who depend on caregivers for medication management. Dupixent requires subcutaneous injection every two weeks after an initial loading dose. EBGLYSS offers a potential advantage here: after its loading phase, maintenance dosing drops to every four weeks, cutting the injection burden in half compared to some competitors. Adbry is also administered subcutaneously, typically every two weeks initially with potential spacing to every four weeks in some patients who respond well. The tradeoff is not simply about convenience.
More frequent injections mean more opportunities for injection-site reactions, more caregiver time, and more chances for a cognitively impaired patient to become anxious or resistant to the process. For a person with dementia who cannot understand why they are being given a shot every two weeks, an every-four-week schedule can meaningfully reduce distress. On the other hand, the biologic with the best efficacy profile for a given patient may require more frequent dosing, and efficacy should generally take priority over convenience when the disease is severe. All of these medications are self-injected or caregiver-administered at home using prefilled syringes or autoinjectors, which eliminates the need for clinic visits for each dose. However, the initial prescription typically requires a dermatologist, and insurance prior authorization can take weeks — a frustrating delay when someone is suffering from severe itch and sleep loss.
Who Should Not Use These Treatments — Warnings and Limitations
These biologics are generally well tolerated, but they are not appropriate for everyone, and there are several limitations that patients and caregivers should understand. Dupixent’s most notable side effect is conjunctivitis, which occurs at higher rates than placebo and can be particularly troublesome for older adults who may already have dry eye disease or other ophthalmologic conditions. Patients on Dupixent who develop persistent eye redness, itching, or tearing should report this to their physician rather than assuming it is unrelated. Nemluvio, because it was only approved in December 2024, has a shorter post-market safety track record than Dupixent. Its clinical trials showed generally manageable side effects, but the long-term safety profile in real-world populations — including older adults with multiple comorbidities — is still being established.
Patients with active infections should not start any of these biologics until the infection is resolved, and live vaccines should generally be avoided during treatment. A critical limitation across all these treatments is cost. Without insurance coverage, these biologics can run tens of thousands of dollars per year. While manufacturer assistance programs exist, navigating them requires paperwork and persistence that can be especially burdensome for older adults living alone or caregivers already stretched thin. Medicare Part D coverage varies, and some patients fall into coverage gaps that make sustained treatment financially unsustainable. None of these drugs cure atopic dermatitis — they manage it, and stopping treatment typically means the disease returns.
EBGLYSS in Younger Patients — What the Latest Pediatric Data Shows
The most recent clinical data on EBGLYSS, reported in March 2026, demonstrated that it is the first and only selective IL-13 inhibitor to deliver positive Phase 3 outcomes in patients aged six months to 18 years with moderate-to-severe atopic dermatitis. The results were striking: 63% of pediatric patients achieved EASI-75 versus 22% on placebo, 44% achieved clear or almost-clear skin versus 15% on placebo, and 39% reached EASI-90 versus 11% on placebo.
While pediatric data may seem tangential to a brain health audience, it matters for two reasons. First, atopic dermatitis often begins in childhood and persists into adulthood and old age, so effective early treatment may reduce the cumulative burden of chronic inflammation and sleep disruption over a lifetime. Second, many grandparents and older caregivers are raising grandchildren with severe eczema, and understanding that effective, well-studied treatments exist can reduce the stress and helplessness that often accompanies caregiving for a child with uncontrolled skin disease.
The Future — Could One Injection Per Year Be Enough?
The most intriguing development on the horizon is APG777, an investigational half-life-extended anti-IL-13 antibody being developed by Apogee Therapeutics. In its Phase 2 APEX trial, APG777 showed significant pruritus improvement as early as Day 3, with an 18.1% reduction versus 4.2% on placebo. At Week 16, patients experienced a 71.0% EASI reduction versus 33.8% on placebo, and roughly two-thirds achieved EASI-75 — described as the highest EASI-75 response rate for any biologic in a global study to date.
What sets APG777 apart from everything currently available is its approximately 77-day half-life, with sustained biomarker inhibition demonstrated up to 12 months. This could potentially allow dosing as infrequently as once per year. For older adults with cognitive impairment, for caregivers managing complex medication regimens, and for anyone who struggles with the ongoing burden of biweekly or monthly injections, a once-yearly treatment would be transformative. APG777 has not yet been approved, and Phase 3 trials will need to confirm these results, but the data so far suggests a genuinely new paradigm in how atopic dermatitis might be managed in the years ahead.
Conclusion
The landscape of injectable treatments for moderate-to-severe atopic dermatitis has expanded rapidly, and the speed at which these biologics work has improved with each new approval. From Dupixent’s itch relief within two days to Nemluvio’s 48-hour itch reduction through direct IL-31 blockade, to EBGLYSS’s favorable dosing schedule and strong pediatric data, patients now have multiple effective options where a decade ago they had essentially none. The investigational APG777, with its potential for once-yearly dosing, suggests the field is far from finished innovating.
For readers focused on brain health and dementia care, the message is straightforward: uncontrolled atopic dermatitis is not just a skin problem. It disrupts sleep, drives chronic inflammation, and degrades quality of life in ways that intersect directly with cognitive health. If you or someone you care for is living with moderate-to-severe eczema that has not responded to topical treatments, a conversation with a dermatologist about these injectable biologics is worth having — sooner rather than later, because the evidence now shows that relief does not have to take months to arrive.
Frequently Asked Questions
How quickly can I expect itch relief from a biologic injection for atopic dermatitis?
It depends on the specific treatment. Dupixent has shown significant itch improvement as early as 2 days after the first injection. Nemluvio demonstrated clinically meaningful itch reduction at 48 hours in about 10.7% of patients versus 2.9% on placebo. EBGLYSS showed meaningful itch relief as early as 2 weeks. Individual responses vary, and full skin clearance typically takes longer than initial itch relief.
Are these injectable treatments safe for older adults?
These biologics are generally well tolerated, but older adults may face specific considerations. Dupixent can cause conjunctivitis, which may complicate existing eye conditions. Nemluvio was only approved in December 2024, so its long-term real-world safety data in elderly populations is still limited. Patients with active infections should not begin treatment, and live vaccines should be avoided during therapy. A dermatologist familiar with the patient’s full medical history should guide the decision.
Does treating atopic dermatitis really help with cognitive health?
The connection is indirect but well-supported. Severe atopic dermatitis causes significant sleep disruption due to chronic itch, and chronic sleep deprivation is independently associated with increased dementia risk and impaired memory consolidation. By reducing itch and improving sleep quality — which these biologics have been shown to do — treatment may help protect cognitive function, though no clinical trial has directly measured dementia outcomes from eczema treatment.
What if the first biologic I try does not work?
Not all patients respond to the same biologic, and switching is a recognized strategy. Because these treatments target different parts of the inflammatory pathway — Dupixent blocks IL-4 and IL-13, Nemluvio targets IL-31, and EBGLYSS selectively inhibits IL-13 — a patient who does not respond to one mechanism may respond to another. Discuss options with your dermatologist before discontinuing treatment, as some biologics need a full 16-week course before efficacy can be properly assessed.
How much do these injections cost without insurance?
These biologics typically cost tens of thousands of dollars per year without insurance. Manufacturer patient assistance programs and copay cards exist for many of them, but navigating the application process requires effort. Medicare Part D coverage varies by plan, and some patients encounter coverage gaps. Discuss cost concerns with your prescribing physician’s office, as many have staff dedicated to helping with prior authorizations and financial assistance.
